Dual selection pressure by drugs and HLA class I-restricted immune responses on human immunodeficiency virus type 1 protease

Journal of Virology

Volumn 81, Issue 6, 2007, Pages 2887-2898

  Mueller, Sandra M ^a,c   Schaetz, Birgit ^a,c   Eismann, Kathrin ^a   Bergmann, Silke ^a   Bauerle, Michael ^a   Schmitt Haendle, Matthias ^a   Walter, Hauke ^b,c   Schmidt, Barbara ^b   Korn, Klaus ^b   Sticht, Heinrich ^b   Spriewald, Bernd ^a   Harrer, Ellen G ^a   Harrer, Thomas ^a,c  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c German Competence Network on HIV/AIDS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 1; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PROTEINASE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIGEN RECOGNITION; ARTICLE; CD8+ T LYMPHOCYTE; DRUG DESIGN; ENZYME LINKED IMMUNOSPOT ASSAY; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS MUTATION;

ALLELES; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DRUG RESISTANCE, VIRAL; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY TESTING; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MOLECULAR SEQUENCE DATA; SELECTION (GENETICS); VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33947360754     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01547-06     Document Type: Article

References (44)

1. Alexander, C. S., W. Dong, K. Chan, N. Jahnke, M. V. O'Shaughnessy, T. Mo, M. A. Piaseczny, J. S. Montaner, and P. R. Harrigan. 2001. HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort. AIDS 15:601-607.
2. Bihl, F., N. Frahm, L. Di Giammarino, J. Sidney, M. John, K. Yusim, T. Woodberry, K. Sango, H. S. Hewitt, L. Henry, C. H. Linde, J. V. Chisholm III, T. M. Zaman, E. Pae, S. Mallal, B. D. Walker, A. Sette, B. T. Korber, D. Heckerman, and C. Brander. 2006. Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J. Immunol. 176:4094-4101.
3. Boehringer Ingelheim Pharmaceuticals. 19 April 2005, posting date. Tipranavir Anti-Viral Drugs Advisory Committee (AVDAC) briefing document. Boehringer Ingelheim Pharmaceuticals, Ingelheim, Germany, http://www.fda.gov /ohrms/dockets/ac/05/briefing/2005-4139b1-02-boehringer.pdf.
4. Casazza, J. P., M. R. Betts, B. J. Hill, J. M. Brenchley, D. A. Price, D. C. Douek, and R. A. Koup. 2005. Immunologic pressure within class I-restricted cognate human immunodeficiency virus epitopes during highly active antiretroviral therapy. J. Virol. 79:3653-3663.
5. Condra, J. H., D. J. Holder, W. A. Schleif, O. M. Blahy, R. M. Danovich, L. J. Gabryelski, D. J. Graham, D. Laird, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, T. Yang, J. A. Chodakewitz, P. J. Deutsch, R. Y. Leavitt, F. E. Massari, J. W. Mellors, K. E. Squires, R. T. Steigbigel, H. Teppler, and E. A. Emini. 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:8270-8276.
6. Del Val, M., H. J. Schlicht, T. Ruppert, M. J. Reddehase, and U. H. Koszinowski. 1991. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell 66:1145-1153.
7. Devereux, J., P. Haeberli, and O. Smithies. 1984. A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res. 12:387-395.
8. Fabio, G., R. Scorza, A. Lazzarin, M. Marchini, M. Zarantonello, A. D'Arminio, P. Marchisio, A. Plebani, R. Luzzati, and P. Costigliola. 1992. HLA-associated susceptibility to HIV-1 infection. Clin. Exp. Immunol. 87: 20-23.
9. Flores-Villanueva, P. O., E. J. Yunis, J. C. Delgado, E. Vittinghoff, S. Buchbinder, J. Y. Leung, A. M. Uglialoro, O. P. Clavijo, E. S. Rosenberg, S. A. Kalams, J. D. Braun, S. L. Boswell, B. D. Walker, and A. E. Goldfeld. 17 April 2001. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc. Natl. Acad. Sci. USA 98:5140-5145. [Epub ahead of print.]
10. Gallant, J. E., P. Z. Gerondelis, M. A. Wainberg, N. S, Shulman, R. H. Hanbrich, M. St. Clair, E. R. Lanier, N. S. Hellmann, and D. D. Richman. 2003. Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir. Ther. 8:489-506.
11. Goulder, P. J., and D. I. Watkins. 2004. HIV and SIV CTL escape: implications for vaccine design. Nat. Rev. Immunol. 4:630-640.
12. Harrer, E. G., S. Bergmann, K. Eismann, M. Rittmaier, A. Goldwich, S. M. Muller, B. M. Spriewald, and T. Harrer. 2005. A conserved HLA B13-restricted cytotoxic T lymphocyte epitope in Nef is a dominant epitope in HLA B13-positive HIV-1-infected patients. AIDS 19:734-735.
13. Holzhutter, H. G., C. Frommel, and P. M. Kloetzel. 1999. A theoretical approach towards the identification of cleavage-determining amino acid motifs of the 20 S proteasome. J. Mol. Biol. 286:1251-1265.
14. John, M., C. B. Moore, I. R. James, and S. A. Mallal. 2005. Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1. Antivir. Ther. 10:551-555.
15. Johnson, V. A., F. Brun-Vezinet, B. Clotet, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D. D. Richman. 2006. Update of the drug resistance mutations in HIV-1: fall 2006. Top. HIV Med. 14:125-130.
16. Karlsson, A. C., S. G. Deeks, J. D. Barbour, B. D. Heiken, S. R. Younger, R. Hoh, M. Lane, M. Sallberg, G. M. Ortiz, J. F. Demarest, T. Liegler, R. M. Grant, J. N. Martin, and D. F. Nixon. 2003. Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. J. Virol. 77:6743-6752.
17. Kiefel, V., and A. Greinacher. 4 November 2006, posting date. Transfusionsmedizin und Immunhämatologie, p. 101-111. University of Rostock, Rostock, Germany, http://www-tmed.med.uni-rostock.de/tmed.pdf.
18. Kiepiela, P., A. J. Leslie, I. Honeyborne, D. Ramduth, C. Thobakgale, S. Chetty, P. Rathnavalu, C. Moore, K. J. Pfafferott, L. Milton, P. Zimbwa, S. Moore, T. Allen, C. Brander, M. M. Addo, M. Altfeld, I. James, S. Mallal, M. Bunce, L. D. Barber, J. Szinger, C. Day, P. Klenerman, J. Mullins, B. Korber, H. M. Coovadia, B. D. Walker, and P. J. Goulder. 2004. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432:769-775.
19. Korber, B. T. M., C. Brander, B. F. Haynes, R. Koup, J. P. Moore, B. D. Walker, and D. I. Watkins (ed.). 2005. HIV molecular immunology 2005. LA-UR 06-0036. Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, NM.
20. Leitner, T., B. Foley, B. Hahn, P. Marx, F. McCutchan, J. Mellors, S. Wolinsky, and B. Korber (ed.). 2005. HIV sequence compendium 2005. LA-UR 06-0680. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
21. Leslie, A., D. Xavanagh, I. Honeyborne, K. Pfafferott, C. Edwards, T. Pillay, L. Hilton, C. Thobakgale, D. Ramduth, R. Draenert, S. Le Gall, G. Luzzi, A. Edwards, C. Brander, A. K. Sewell, S. Moore, J. Mullins, C. Moore, S. Mallal, N. Bhardwaj, K. Yusim, R. Phillips, P. Klenerman, B. Korber, P. Kiepiela, B. Walker, and P. Goulder. 2005. Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J. Exp. Med. 201:891-902.
22. Leslie, A. J., K. J. Pfafferott, P. Chetty, R. Draenert, M. M. Addo, M. Feeney, Y. Tang, E. C. Holmes, T. Allen, J. G. Prado, M. Altfeld, C. Brander, C. Dixon, D. Ramduth, P. Jeena, S. A. Thomas, A. St. John, T. A. Roach, B. Kupfer, G. Luzzi, A. Edwards, G. Taylor, H. Lyall, G. Tudor-Williams, V. Novelli, J. Martinez-Picado, P. Kiepiela, B. D. Walker, and P. J. Goulder. 2004. HIV evolution: CTL escape mutation and reversion after transmission. Nat. Med. 10:282-289.
23. Mason, R. D., M. I. Bowmer, C. M. Howley, M. Gallant, J. C. Myers, and M. D. Grant. 2004. Antiretroviral drug resistance mutations sustain or enhance CTL recognition of common HIV-1 Pol epitopes. J. Immunol. 172: 7212-7219.
24. McKinney, D. M., R. Skvoretz, B. D. Livingston, C. C. Wilson, M. Anders, R. W. Chesnut, A. Sette, M. Essex, V. Novitsky, and M. J. Newman. 2004. Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL. J. Immunol. 173:1941-1950.
25. Meiselbach, H., A. H. Horn, T. Harrer, and H. Sticht. 2006. Insights into amprenavir resistance in E35D HIV-1 protease mutation from molecular dynamics and binding free-energy calculations. J. Mol. Model. 23:23.
26. Milicic, A., D. A Price, P. Zimbwa, B. L. Booth, H. L. Brown, P. J. Easterbrook, K, Olsen, N. Robinson, U. Gileadi, A. K. Sewell, V. Cerundolo, and R. E. Phillips. 2005. CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef. J. Immunol. 175:4618-4626.
27. Molla, A, M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H. M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
28. Moore, C. B., M. John, I. R. James, F. T. Christiansen, C. S. Witt, and S. A Mallal. 2002. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296:1439-1443.
29. Pedron, B., K. Yakouben, D. Adjaoud, A. Auvrignon, J. Landraan, V. Guerin, G. Leverger, E. Vilmer, and G. Sterkers. 18 March 2005. Listing of common HLA alleles and haplotypes based on the study of 356 families residing in the Paris, France, area: implications for unrelated hematopoietic stem cell donor selection. Hum. Immunol. 66:721-731. [Epub ahead of print.]
30. Propato, A., E. Schiaffella, E. Vicenzi, V. Francavilla, L. Baloni, M. Paroli, L. Finocchi, N. Tanigaki, S. Ghezzi, R. Ferrara, R. Chesnut, B. Livingston, A. Sette, R. Paganelli, F. Ainti, G. Poli, and V. Barnaba. 2001. Spreading of HIV-specific CD8+ T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity. Hum. Immunol. 62:561-576.
31. Rammensee, H., J. Bachmann, N. P. Emmerich, O. A. Bachor, and S. Stevanovic. 1999. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213-219.
32. Ratner, L., W. Haseltine, R. Patarca, K. J. Livak, B. Starckb, S. F. Josephs, E. R. Doran, J. A. Rafalski, E. A. Whitehorn, K. Baumeister, et al. 1985. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313: 277-284.
33. Rodriguez, W. R., M. M. Addo, A. Rathod, C. A. Fitzpatrick, X. G. Yu, B. Perkins, E. S. Rosenberg, M. Altfeld, and B. D. Walker. 2004. CD8+ T lymphocyte responses target functionally important regions of protease and integrase in HIV-1 infected subjects. J. Transl. Med. 2:15. http://www .translational-medicine.com.
34. Rohowsky-Kochan, C., J. Skurnick, D. Molinaro, and D. Louria. 1998. HLA antigens associated with susceptibility/resistance to HIV-1 infection. Hum. Immunol. 59:802-815.
35. Saitou, N., and M. Nei. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4:406-425.
36. Samri, A., G. Haas, J. Duntze, J. M. Bouley, V. Calvez, C. Katlama, and B. Autran. 2000. Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells. J. Virol. 74:9306-9312.
37. Schmidt, B., H. Walter, B. Moschik, C. Paatz, K. van Vaerenbergh, A. M. Vandamme, M. Schmitt, T. Harrer, K. Uberla, and K. Korn. 2000. Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance. AIDS 14:1731-1738.
38. Schmitt, M., E. Harrer, A. Goldwich, M. Bauerle, I. Graedner, J. R. Kalden, and T. Harrer. 2000. Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes. AIDS 14:653-658.
39. Sette, A, and J. Sidney. 1999. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50:201-212.
40. Sidney, J., S. Southwood, V. Pasquetto, and A. Sette. 2003. Simultaneous prediction of binding capacity for multiple molecules of the HLA B44 supertype. J. Immunol. 171:5964-5974.
41. Stratov, I., C. J. Dale, S. Chea, J. McCluskey, and S. J. Kent. 2005. Induction of T-cell immunity to antiretroviral drug-resistant human immunodeficiency virus type 1. J. Virol. 79:7728-7737.
42. Tang, J., and R. A. Kaslow. 2003. The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy. AIDS 17:S51-S60.
43. Turner, D., J. M. Schapiro, B. G. Brenner, and M. A. Wainberg, 2004. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients. Antivir. Ther. 9:301-314.
44. Walter, H., B. Schmidt, K. Korn, A. M. Vandamme, T. Harrer, and K. Uberla. 1999. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J. Clin. Virol. 13:71-80.